SRPT
USDSarepta Therapeutics Inc. Common Stock (DE)
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$15.310
Максимум
$17.750
Минимум
$15.080
Объем
2.09M
Фундаментальные показатели компании
Рыночная капитализация
1.7B
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
7.10M
Биржа
NMS
Валюта
USD
52-недельный диапазон
Связанные новости
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.
Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15
Baird analyst Brian Skorney maintains Sarepta Therapeutics with a Neutral and lowers the price target from $21 to $15.
Futures tumble after Wall St banks warn of market pullback, Palantir slides
U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.
Sarepta slumps as gene therapy setback adds to drug pipeline woes
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline.
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $16
Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics with a Neutral and raises the price target from $15 to $16.
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025.
Связанные акции
MHO
M/I Homes Inc.
PRIM
Primoris Services Corporation
COLL
Collegium Pharmaceutical Inc.
FTAIN
FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
NKGNW
NKGen Biotech Inc. Warrants
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.